Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18294 | 1.00 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL27388627 | 0.93 | USP2 (0.62) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL16612394 | 0.93 | USP2 (0.62) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL2223924 | 0.91 | USP2 (0.60) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL6061822 | 0.91 | USP2 (0.60) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL2915295 | 0.91 | USP2 (0.60) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL2430769 | 0.91 | USP2 (0.60) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL8874348 | 0.91 | USP2 (0.60) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL17344112 | 0.91 | USP2 (0.60) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL334091 | 0.91 | USP2 (0.60) | USP2SMN1; SMN2HPGDEPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111517998-B | Zwitterionic surfactant and preparation method thereof | 杨凌单色生物科技有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-111517993-B | Zwitterionic fluorocarbon surfactant and preparation method thereof | 杨凌单色生物科技有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-111389305-B | Amphoteric ion organic silicon surfactant and preparation method thereof | 杨凌单色生物科技有限公司 | 2021-09-07 | — | — | CN | claimed |
| CN-111517993-A | Zwitterionic fluorocarbon surfactant and preparation method thereof | 杨凌单色生物科技有限公司 | 2020-08-11 | — | — | CN | claimed |
| CN-111517998-A | Zwitterionic surfactant and preparation method thereof | 杨凌单色生物科技有限公司 | 2020-08-11 | — | — | CN | claimed |
| CN-111389305-A | Amphoteric ion organic silicon surfactant and preparation method thereof | 杨凌单色生物科技有限公司 | 2020-07-10 | — | — | CN | claimed |
| EP-1794129-B1 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-30 | — | — | EP | claimed |
| EP-1794129-A4 | SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-02 | — | — | EP | claimed |
| US-7402670-B2 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | claimed |
| EP-1794129-A2 | SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-13 | — | — | EP | claimed |
| WO-2006039383-A2 | SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | WO | claimed |
| US-20060069250-A1 | Synthesis by chiral diamine-mediated asymmetric alkylation | DENG XIAOHU | 2006-03-30 | — | — | US | claimed |
| EP-0595924-B1 | PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LAB (US) | 1999-04-14 | — | — | EP | claimed |
| EP-0350131-A2 | New 1,4-diazepine derivatives having anti-ulcer activity | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1990-01-10 | — | — | EP | claimed |
| EP-4396305-B1 | SYNTHESIS OF MDMA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDMA ISOMERS | EMPATHBIO INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12492178-B2 | Stable polymorph of R-MDMA HCl | EMPATHBIO, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4615828-A2 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EmpathBio, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-5140024-A | Thienofuro- or thienodiazepines and pyridofuro- or thienodizsepines; antisecretory and -inflammatory agents; gastrointestinal disorders | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1992-08-18 | — | — | US | disclosed |
| US-4985423-A | New 1,4-diazepine derivatives having anit-ulcer activity | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1991-01-15 | — | — | US | disclosed |
| EP-0350131-A2 | New 1,4-diazepine derivatives having anti-ulcer activity | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069250-A1 | Synthesis by chiral diamine-mediated asymmetric alkylation | SRM, SMOX, DDC | USP2 1919/4885SMN1; SMN2 3550/4885HPGD 2209/4885 |
| US-12492178-B2 | Stable polymorph of R-MDMA HCl | HTR3A, OPRM1, HTR3B | USP2 2466/4885SMN1; SMN2 1250/4885HPGD 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.